8-K: Cencora Repurchases $400 Million in Shares from Walgreens, Raises Fiscal Year 2024 Earnings Guidance

Cencora has repurchased approximately $400 million of its common stock from Walgreens Boots Alliance Holdings LLC and raised its fiscal year 2024 adjusted diluted earnings per share guidance.

Summary

• Cencora, Inc. entered into a share repurchase agreement with Walgreens Boots Alliance Holdings LLC to repurchase 1,859,390 shares of its common stock at a price of $215.1244 per share.
• The total cost of the repurchase was approximately $400 million, and the transaction was completed on May 24, 2024.
• Following the repurchase, Walgreens Boots Alliance Holdings LLC now owns approximately 12% of Cencora's outstanding shares.
• Cencora has updated its fiscal year 2024 adjusted diluted earnings per share guidance to a range of $13.35 to $13.55, up from the previous range of $13.30 to $13.50.
• The increased guidance reflects a lower weighted average diluted share count, partially offset by higher net interest expense due to the cash used for the share repurchase.
• Cencora has completed approximately $550 million of share repurchases in the month of May.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the share repurchase and increased earnings guidance. The company is demonstrating confidence in its financial position and future prospects.

Positives

• The share repurchase reduces the number of outstanding shares, which can increase earnings per share.
• The company's updated earnings guidance indicates a positive outlook for the fiscal year.
• The company has demonstrated an opportunistic approach to share repurchases.
• The company has completed a significant amount of share repurchases in May.

Negatives

• The share repurchase was funded with cash, which will reduce the company's investment balances and increase net interest expense.

Risks

• The company's forward-looking statements are subject to uncertainty and changes in circumstances.
• Actual results could vary materially from the company's estimates.
• The company's financial performance is subject to risks and uncertainties detailed in its annual report.

Future Outlook

Cencora has raised its fiscal year 2024 adjusted diluted earnings per share guidance to $13.35 to $13.55, reflecting a lower weighted average diluted share count, partially offset by higher net interest expense.

Management Comments

• The transaction is an example of the company's opportunistic approach to share repurchases.

Industry Context

Share repurchases are a common method for companies to return value to shareholders and can signal management's confidence in the company's future prospects. The pharmaceutical industry is known for its large cash flows and share repurchases are a common use of excess cash.

Comparison to Industry Standards

• Many large pharmaceutical companies engage in share repurchase programs, including companies like McKesson and Cardinal Health.
• The size of Cencora's repurchase is significant, but not unusual for a company of its size and profitability.
• The updated earnings guidance is a positive sign, indicating that the company is performing well compared to its own previous expectations.

Related Party Transactions

• The share repurchase agreement was between Cencora and Walgreens Boots Alliance Holdings LLC, a significant shareholder.

Stakeholder Impact

• Shareholders may benefit from the increased earnings per share and the company's positive outlook.
• The company's employees may be positively impacted by the company's strong financial performance.
• The company's suppliers and customers may view the company's financial strength as a positive sign.

Next Steps

• The company will hold the repurchased shares in treasury.
• The company will continue to monitor its financial performance and may consider further share repurchases in the future.

Key Dates

Keywords

share repurchase, earnings guidance, common stock, Walgreens Boots Alliance, fiscal year 2024, adjusted diluted earnings per share, treasury stock